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When a patient presents to a clinician with dizziness, it can be difficult for the patient to describe 29 
their symptoms in a clear manner, and clinical examination often yields entirely normal results.  30 
Ideally, it would be favourable to measure key physiological parameters during their episodes of 31 
dizziness.  From a clinical perspective, this would allow a more timely and more accurate diagnosis.  32 
From a research perspective, it would allow a greater understanding of how the vestibular system 33 
malfunctions as a consequence of vestibular disease.  The authors of this report have been funded 34 
by the UK Medical Research Council to develop and test novel technology to measure, record and 35 
analyse key physiological parameters provided by the dizzy individual during episode of dizziness 36 
whist active in the community.  We provide the context to evolving work in this field, the outcome of 37 













Dizziness is a common complaint that places a significant burden on health services worldwide.1  50 
Dizziness affects 20–50% of individuals during their lives and up to 10% of affected individuals 51 
experience vertigo.2 In 80% of affected individuals, vertigo results in a medical consultation, 52 
interruption of daily activities, or sick leave.3 53 
 54 
 55 
Vestibular telemetry 56 
 57 
Contemporary methods to evaluate the dizzy patient only provide a snapshot of vestibular function 58 
when performed in the absence of a 'dizzy attack'.  Nystagmus is a key clinical sign that should be 59 
documented when assessing patients with vertigo and various patterns of nystagmus are produced 60 
as a consequence of different disease processes. If it were possible to continuously monitor dizzy 61 
patients in the community, the presence of a nystagmus pattern could aid diagnosis. We term this 62 
diagnostic process, 'vestibular telemetry'. This approach is analogous to the 24-hour ECG tape used 63 
to identify cardiac arrhythmias. 64 
 65 
 66 
The CAVA system 67 
 68 
The CAVA (Continuous Ambulatory Vestibular Assessment) system consists of a wearable device and 69 
computer algorithms to identify nystagmus.  The device includes a single-use sensor array that 70 
adheres to the face to capture horizontal and vertical eye-movements, and a reusable module 71 
containing an accelerometer, microcomputer, data storage, battery, and connection port (Figure 1).  72 
Eye-movements are recorded via the corneo-retinal potential generated by the eyes. A sampling 73 
 4 
rate of 42 Hz is used; close to a typical lower-end for videonystagmography. This rate reconciles data 74 
storage requirements against the level of resolvable detail. Device calibration is not required to 75 
identify nystagmus, but an average calibration value is assumed when calculating slow phase 76 
velocities. 77 
 78 
The CAVA device was developed to allow continuous recording of eye and head movements for 23 79 
hours a day, for 30-days, in the community. Patients remove the device each morning for an hour 80 
and then reapply it to themselves. The following findings were obtained from two clinical 81 
investigations which were reviewed and approved by the NHS Health Research Authority’s London-82 
Dulwich Research Ethics Committee (IRAS: 261099 and 240847). 83 
 84 
We initially tested the CAVA system on a group of healthy individuals to evaluate the suitability of 85 
the device, and our algorithms’ accuracy at detecting nystagmus induced using an optokinetic video 86 
stimulus viewed on a mobile phone.4 The algorithms detect the presence of nystagmus using a novel 87 
combination of machine learning techniques, and then bespoke analysis routines quantify its more 88 
detailed characteristics.5 The CAVA system consistently, precisely and reliably identified periods of 89 
induced nystagmus in both stationary and moving subjects with a sensitivity and specificity of 99.1% 90 
(95% CI: 95.13% to 99.98%) and 98.6% (95% CI: 96.54% to 99.63%), respectively.  The system could 91 
also identify the frequency and beat direction of nystagmus.5 92 
 93 
Other technologies have been developed to monitor dizziness in the community but have suffered 94 
from fundamental limitations, prohibiting continuous wear due to limited data storage, insufficient 95 
portability and inadequate battery life. The CAVA device is small enough to be worn for thirty days, 96 
stores more than a month’s worth of data, and requires a single battery change after fifteen days. 97 
Technologies employing videonystagmography require the eyes to remain open, but patients often 98 
close their eyes during vertigo and while asleep. Devices requiring donning or activation upon the 99 
 5 
onset of dizziness rely on having the device to hand and being physically capable of doing so; 100 
challenging for elderly individuals or those experiencing severe symptoms. 101 
 102 
 103 
Clinical Applications 104 
 105 
We are currently investigating the applicability of the CAVA system in patients reporting vertigo. We 106 
have identified quantifiable differences between the nystagmus produced by our target conditions: 107 
Ménière’s disease, vestibular migraine and Benign Paroxysmal Positional Vertigo (BPPV).6 Figures 2 108 
to 4 show nystagmus traces produced by these conditions. We have discovered that nystagmus 109 
produced during an attack of Ménière’s disease occurs in short episodes lasting several hours, during 110 
which the “beat” direction alternates in relation to the affected ear.7 By contrast, nystagmus during 111 
a vestibular migraine attack is shorter in duration and its slow phase velocities are generally lower. 112 
The nystagmus of BPPV is even shorter in duration and is induced by acceleration of the head, as 113 
confirmed by CAVA’s accelerometer signals. 114 
 115 
We have recorded an entire episode of vertigo in a patient with Ménière’s disease.7 Because we 116 
recorded eye movements before, during and after the attack, we have discovered a possible 117 
prodromal phase.  If this is a consistent feature of Ménière’s disease, it could be exploited to warn 118 
patients of an impending attack.  In another study, we analysed nystagmus traces from different 119 
patients with Ménière’s disease, revealing how the characteristics of nystagmus could aid decision 120 
making with respect to treatment. 8 121 
 122 
 123 
Future developments 124 
 125 
 6 
The CAVA system fulfils an unmet clinical need to provide a long-term, objective record of a patient’s 126 
vertigo. Such a record could also be used to confirm reports of ‘dizziness’ following work-related 127 
head injuries or road accidents. The CAVA device has the potential to aid the diagnosis and 128 
understanding of many areas of vestibular medicine, conditions outside the vestibular system, non-129 
vestibular areas of medical research (e.g. sleep medicine), and beyond (e.g. driver alertness 130 
monitoring). 131 
 132 
The diagnosis of Ménière’s disease and vestibular migraine is contentious.  Many tests are often 133 
required, including radiological investigations, audiometry and other specialist vestibular tests. As 134 
more nystagmus data become available, in addition to identifying nystagmus patterns that are 135 
consistent with conditions such as Ménière’s disease and vestibular migraine, it might be possible to 136 
create universal diagnostic criteria for these conditions, as well for disease subtyping, grading and 137 
staging. 138 
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Figure 1: The CAVA device. Two electrodes either side of the eyes record horizontal eye movement, 174 
two above and below one eye record vertical eye movement, and a fifth beneath the right ear 175 
provides a reference voltage. 176 
 177 
Figure 2: Left-beating nystagmus during an attack of Ménière's Disease. Fast/slow phases are shown  178 
in red/green. The attack occurred over about three hours and consisted of eight separate episodes 179 
of nystagmus. 180 
 181 
Figure 3: Right-beating nystagmus during a vestibular migraine attack. Fast/slow phases are shown  182 
in red/green. Compared to Figure 2, slow phase durations are longer and slow phase velocities are 183 
lower. The attack lasted about an hour. 184 
 185 
Figure 4: Nystagmus during a BPPV attack. This nystagmus is oscillatory without obvious fast or slow 186 
phases (red boxes). After starting, the nystagmus briefly subsided before resuming again. The 187 
duration of the nystagmus was approximately twenty seconds. 188 
